Jacques Neefjes

Jacques Neefjes


Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2011 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
JNJacques Neefjes
Jacques Neefjes
MJMarlieke L. M. Jongsma
Marlieke L. M. Jongsma
PPPetra Paul
Petra Paul
NNNn Nn
Nn Nn

24 April 2006 in Journal of Experimental Medicine
Verified
Journal Article
Open access
EREric A. Reits
Eric A. Reits
JHJames W. Hodge
James W. Hodge
CHCarla A. Herberts
Carla A. Herberts
TGTom A. Groothuis
Tom A. Groothuis
MCMala Chakraborty
Mala Chakraborty
JNJacques Neefjes
Jacques Neefjes
Radiotherapy is one of the most successful cancer therapies. Here the effect of irradiation on antigen presentation by MHC class I molecules was studied. Cell surface expression of MHC class I molecules was increased for many days in a radiation dose-dependent manner as a consequence of three responses. Initially, enhanced degradation of existing proteins occurred which resulted in an increased intracellular peptide pool. Subsequently, enhanced translation due to activation of the mammalian target of rapamycin pathway resulted in increased peptide production, antigen presentation, as well as cytotoxic T lymphocyte recognition of irradiated cells. In addition, novel proteins were made in response to γ-irradiation, resulting in new peptides presented by MHC class I molecules, which were recognized by cytotoxic T cells. We show that immunotherapy is successful in eradicating a murine colon adenocarcinoma only when preceded by radiotherapy of the tumor tissue. Our findings indicate that directed radiotherapy can improve the efficacy of tumor immunotherapy.

1 November 2016 in Trends in Immunology
Verified
Journal Article
Closed access
KRKenneth L. Rock
Kenneth L. Rock
EREric Reits
Eric Reits
JNJacques Neefjes
Jacques Neefjes

2 August 1990 in Nature
Verified
Journal Article
Closed access
PDF file
HLH G Ljunggren
H G Ljunggren
NSN J Stam
N J Stam
COC Ohlén
C Ohlén
JNJacques Neefjes
Jacques Neefjes
PHP Höglund
P Höglund
KKK Kärre
K Kärre

1 October 2001 in Current Biology
Verified
Journal Article
Closed access
IJIngrid Jordens
Ingrid Jordens
MFMar Fernandez-Borja
Mar Fernandez-Borja
MMMarije Marsman
Marije Marsman
SDSimone Dusseljee
Simone Dusseljee
LJLennert Janssen
Lennert Janssen
JNJacques Neefjes
Jacques Neefjes

29 June 2009 in Journal of Cell Biology
Verified
Journal Article
Open access
NRNuno Rocha
Nuno Rocha
CKCoenraad Kuijl
Coenraad Kuijl
RKRik Van Der Kant
Rik Van Der Kant
LJLennert Janssen
Lennert Janssen
DHDiane Houben
Diane Houben
JNJacques Neefjes
Jacques Neefjes
Late endosomes (LEs) have characteristic intracellular distributions determined by their interactions with various motor proteins. Motor proteins associated to the dynactin subunit p150Glued bind to LEs via the Rab7 effector Rab7-interacting lysosomal protein (RILP) in association with the oxysterol-binding protein ORP1L. We found that cholesterol levels in LEs are sensed by ORP1L and are lower in peripheral vesicles. Under low cholesterol conditions, ORP1L conformation induces the formation of endoplasmic reticulum (ER)–LE membrane contact sites. At these sites, the ER protein VAP (VAMP [vesicle-associated membrane protein]-associated ER protein) can interact in trans with the Rab7–RILP complex to remove p150Glued and associated motors. LEs then move to the microtubule plus end. Under high cholesterol conditions, as in Niemann-Pick type C disease, this process is prevented, and LEs accumulate at the microtubule minus end as the result of dynein motor activity. These data explain how the ER and cholesterol control the association of LEs with motor proteins and their positioning in cells.